NCT05677139Completed
A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
Asthma Control in Severe Asthma Patients Treated With Tezepelumab: A Prospective, Observational, Real-World Evidence Study (ASCENT)
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
A study involving primary data collection within real-world settings of participants who initiate treatment with tezepelumab for severe uncontrolled asthma. This study will complement evidence obtained from randomized controlled trials and provide new data focusing on the holistic and patient reported outcome (PRO).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 513 (actual)
- First submitted
- 29 Nov 2022
- Start date
- 13 Dec 2022
- Primary completion date
- 27 Feb 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT05677139
What you commit to
- Study type: Observational
- Participants enrolled: 513
- From 13 Dec 2022 to the primary completion date, 27 Feb 2026
- 58 sites in 9 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants on concurrent biologics for asthma at the time of receiving the first dose of Tezepelumab will be excluded except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment)
Other
- Any contraindication to Tezepelumab
- Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months
- Pregnancy or lactation period.
Who the study is looking for
- Male or female participants aged 12 years or older
- Provision of signed and dated written informed consent, including assent for minors
- Prescribed treatment with Tezepelumab
- Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses
- Received at least one prescription of medium-dose to high-dose inhaled corticosteroids (ICS) during the 52 weeks prior to enrolment date
- Use of additional asthma maintenance controller medication(s) for at least 52 weeks prior to enrolment date
- Documented history of at least 1 asthma exacerbations during the 52 weeks prior to enrolment date
- Individuals with ACQ-6 score ≥ 1.5 (indicating inadequate asthma symptom control) at enrolment or up to 12 weeks before enrolment
- Participants currently receiving care from pulmonologists and/or allergists
- Participants who are able to understand and complete the ePROs
- Availability of participants medical records for asthma exacerbation and Healthcare Resource Utilization (HCRU) for the 52 weeks prior to Tezepelumab initiation
Age in the registry: 12 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (58)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.